TY - JOUR
T1 - Immune modulation by danazol in autoimmune thrombocytopenia
AU - Mylvaganam, Ravindra
AU - Ahn, Yeon S.
AU - Harrington, William J.
AU - Kim, Chae I.
N1 - Funding Information:
r This work was supported by the Veterans Administration Merit Review Award 0215-01 and research funds given in honor of Mary Beth Weiss. Kenneth Chasen. Steven Andrew De Young. and James and Vedna Welch.
PY - 1987/3
Y1 - 1987/3
N2 - Danazol, an attenuated androgen, has recently been introduced into the treatment of autoimmune thrombocytopenia. We studied its effects on T helper/inducer (Thi) and T suppressor/cytotoxic (Tsc) lymphocytes in these patients. Prospectively nine patients were studied with their T-cell subsets measured before and during danazol therapy. Increases in the percentage of Thi lymphocytes (P < 0.05) and Thi/Tsc ratios (P < 0.001) were observed at 1 and 3 months of treatment. Retrospectively T-cell subset data on 30 patients not treated with danazol and 36 patients on danazol were compared with those of 35 normal controls. The group not on danazol had lower percentages of Pan T (P < 0.05), Thi (P < 0.002), and Thi/Tsc ratios (P < 0.00005), and had higher percentages of Tsc lymphocytes (P < 0.01), than those of controls. In the group treated with danazol the percentages of Pan T, Thi, and Tsc lymphocytes were similar to those of controls. The percentage of Thi in the treated group was higher (P < 0.002) than in the untreated group. Thus, danazol appears to be an effective immune modulator, correcting the abnormality of T-cell subsets seen in autoimmune thrombocytopenia by increasing the percentage of Thi lymphocytes.
AB - Danazol, an attenuated androgen, has recently been introduced into the treatment of autoimmune thrombocytopenia. We studied its effects on T helper/inducer (Thi) and T suppressor/cytotoxic (Tsc) lymphocytes in these patients. Prospectively nine patients were studied with their T-cell subsets measured before and during danazol therapy. Increases in the percentage of Thi lymphocytes (P < 0.05) and Thi/Tsc ratios (P < 0.001) were observed at 1 and 3 months of treatment. Retrospectively T-cell subset data on 30 patients not treated with danazol and 36 patients on danazol were compared with those of 35 normal controls. The group not on danazol had lower percentages of Pan T (P < 0.05), Thi (P < 0.002), and Thi/Tsc ratios (P < 0.00005), and had higher percentages of Tsc lymphocytes (P < 0.01), than those of controls. In the group treated with danazol the percentages of Pan T, Thi, and Tsc lymphocytes were similar to those of controls. The percentage of Thi in the treated group was higher (P < 0.002) than in the untreated group. Thus, danazol appears to be an effective immune modulator, correcting the abnormality of T-cell subsets seen in autoimmune thrombocytopenia by increasing the percentage of Thi lymphocytes.
UR - http://www.scopus.com/inward/record.url?scp=0023098894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023098894&partnerID=8YFLogxK
U2 - 10.1016/0090-1229(87)90016-X
DO - 10.1016/0090-1229(87)90016-X
M3 - Article
C2 - 3493865
AN - SCOPUS:0023098894
VL - 42
SP - 281
EP - 287
JO - Clinical Immunology
JF - Clinical Immunology
SN - 1521-6616
IS - 3
ER -